BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 34013383)

  • 21. Clinicopathological characteristics and mutation profile of BRAF and NRAS mutation in cutaneous melanomas in the Western Turkish population.
    Evrenos MK; Temiz P; Çam FS; Yaman M; Yoleri L; Ermertcan AT
    Turk J Med Sci; 2018 Oct; 48(5):973-979. PubMed ID: 30384563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of BRAF mutations in primary melanoma growth rate and survival.
    Mar VJ; Liu W; Devitt B; Wong SQ; Dobrovic A; McArthur GA; Wolfe R; Kelly JW
    Br J Dermatol; 2015 Jul; 173(1):76-82. PubMed ID: 25752325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of CCND1 alterations during the progression of cutaneous malignant melanoma.
    Vízkeleti L; Ecsedi S; Rákosy Z; Orosz A; Lázár V; Emri G; Koroknai V; Kiss T; Ádány R; Balázs M
    Tumour Biol; 2012 Dec; 33(6):2189-99. PubMed ID: 23001925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between dermoscopic and reflectance confocal microscopy features of cutaneous melanoma with BRAF mutational status.
    Bombonato C; Ribero S; Pozzobon FC; Puig-Butille JA; Badenas C; Carrera C; Malvehy J; Moscarella E; Lallas A; Piana S; Puig S; Argenziano G; Longo C
    J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):643-649. PubMed ID: 27790766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical, environmental and histological distribution of BRAF, NRAS and TERT promoter mutations among patients with cutaneous melanoma: a retrospective study of 563 patients.
    Manrique-Silva E; Rachakonda S; Millán-Esteban D; García-Casado Z; Requena C; Través V; Kumar R; Nagore E
    Br J Dermatol; 2021 Mar; 184(3):504-513. PubMed ID: 32506424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dermoscopy and confocal microscopy for metachronous multiple melanomas: morphological, clinical, and molecular correlations.
    Colombino M; Paliogiannis P; Pagliarello C; Cossu A; Lissia A; Satta R; Mazzoni L; Magi S; Sini MC; Manca A; Casula M; Doneddu V; Palmieri G; Stanganelli I
    Eur J Dermatol; 2018 Apr; 28(2):149-156. PubMed ID: 29180316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs.
    Wong CW; Fan YS; Chan TL; Chan AS; Ho LC; Ma TK; Yuen ST; Leung SY;
    J Clin Pathol; 2005 Jun; 58(6):640-4. PubMed ID: 15917418
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
    Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
    J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas.
    Kannengiesser C; Spatz A; Michiels S; Eychène A; Dessen P; Lazar V; Winnepenninckx V; Lesueur F; Druillennec S; Robert C; van den Oord JJ; Sarasin A; Bressac-de Paillerets B;
    Mol Oncol; 2008 Apr; 1(4):425-30. PubMed ID: 19383316
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.
    Lee JH; Choi JW; Kim YS
    Br J Dermatol; 2011 Apr; 164(4):776-84. PubMed ID: 21166657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss of membranous expression of beta-catenin is associated with tumor progression in cutaneous melanoma and rarely caused by exon 3 mutations.
    Demunter A; Libbrecht L; Degreef H; De Wolf-Peeters C; van den Oord JJ
    Mod Pathol; 2002 Apr; 15(4):454-61. PubMed ID: 11950921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinicopathologic findings and BRAF mutation in cutaneous melanoma in young adults.
    Estrozi B; Machado J; Rodriguez R; Bacchi CE
    Appl Immunohistochem Mol Morphol; 2014 Jan; 22(1):57-64. PubMed ID: 24471189
    [TBL] [Abstract][Full Text] [Related]  

  • 33. β-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas.
    Nsengimana J; Laye J; Filia A; O'Shea S; Muralidhar S; Poźniak J; Droop A; Chan M; Walker C; Parkinson L; Gascoyne J; Mell T; Polso M; Jewell R; Randerson-Moor J; Cook GP; Bishop DT; Newton-Bishop J
    J Clin Invest; 2018 May; 128(5):2048-2063. PubMed ID: 29664013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas.
    Shinozaki M; Fujimoto A; Morton DL; Hoon DS
    Clin Cancer Res; 2004 Mar; 10(5):1753-7. PubMed ID: 15014028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.
    Saldanha G; Potter L; Daforno P; Pringle JH
    Clin Cancer Res; 2006 Aug; 12(15):4499-505. PubMed ID: 16899595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site.
    Platz A; Egyhazi S; Ringborg U; Hansson J
    Mol Oncol; 2008 Apr; 1(4):395-405. PubMed ID: 19383313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Implication of BRAF V600E and CTNNB1 gene mutations in the pathological classification of craniopharyngioma].
    Xu SS; Wang LM; Zhao LH; He ZL; Gong LP; Lu DH; Teng LH
    Zhonghua Bing Li Xue Za Zhi; 2019 Sep; 48(9):682-687. PubMed ID: 31495087
    [No Abstract]   [Full Text] [Related]  

  • 38. Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma.
    Thomas NE; Edmiston SN; Alexander A; Millikan RC; Groben PA; Hao H; Tolbert D; Berwick M; Busam K; Begg CB; Mattingly D; Ollila DW; Tse CK; Hummer A; Lee-Taylor J; Conway K
    Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):991-7. PubMed ID: 17507627
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi.
    Uribe P; Andrade L; Gonzalez S
    J Invest Dermatol; 2006 Jan; 126(1):161-6. PubMed ID: 16417232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRAF mutations might be more common than supposed in vulvar melanomas.
    Wylomanski S; Denis MG; Théoleyre S; Bouquin R; Vallée A; Knol AC; Saint-Jean M; Peuvrel L; Dréno B; Quéreux G
    Exp Dermatol; 2018 Feb; 27(2):210-213. PubMed ID: 29178146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.